Targeting histone methyltransferase enhancer of zeste homolog‐2 inhibits renal epithelial‐mesenchymal transition and attenuates renal fibrosis

What is it about?

Although numerous studies have demonstrated the importance of injured tubular epithelial cells in the development and progression of CKD, the contribution of an epithelial-mesenchymal transition (EMT) undergone by renal epithelial cells during kidney fibrosis is still controversial. In this study, we found that the histone methyltransferase EZH2 (Enhancer of Zeste Homolog 2) activation contributes to renal EMT and fibrosis through activation of multiple signaling pathways and suggest that EZH2 would be a novel therapy for treatment of renal fibrosis.

Featured Image